Slide 1: Epidemiology
Epidemiology This Epidemiology appendix contains estimates of patient data for a number of diseases and potential indications relevant for select AstraZeneca in-market products and pipeline projects. All data are based on reliable sources generally recognised and used by AstraZeneca for planning pur
Slide 2: Asthma
Asthma US EU5 Japan + China prevalence prevalence prevalence 18.9m 29.4m 21.9m diagnosed diagnosed diagnosed 13.9m 20.4m 16.6m treated treated treated 11.8m 18.6m 10.3m GINA 1 GINA 1 GINA 1 2.5m 4.0m 2.2m GINA 2 GINA 2 GINA 2 1.4m 2.2m 1.2m GINA 3 GINA 3 GINA 3 2.2m 3.5m 1.9m GINA 4 GINA 4 GINA 4 5.
Slide 3: COPD
COPD US EU5 Japan + China prevalence prevalence prevalence 16.5m 21.8m 35.9m diagnosed diagnosed diagnosed 7.6m 13.2m 15.2m GOLD A GOLD A GOLD A 1.9-3.0m 3.3-5.3m 3.8-6.1m GOLD B GOLD B GOLD B 1.1-2.3m 2.0-4.0m 2.3-4.6m GOLD C GOLD C GOLD C 0.4-1.9m 0.7-3.3m 0.8-3.8m GOLD D GOLD D GOLD D 1.9-3.0m 3.
Slide 4: Lesinurad
Lesinurad Gout US* EU5* Japan** prevalence prevalence prevalence 10.5m 13.1m ~2.9m* diagnosed diagnosed diagnosed 6.5m 6.5m 2.9m chronic ULT treated chronic ULT treated chronic ULT treated 4.3m 4.1m 2.1m ULT: Urate Lowering Therapy Due to hyperuricemia treatment, overall gout prevalence remains simi
Slide 5: Brodalumab
Brodalumab Psoriasis (PsO) and Psoriatic Arthritis (PsA) US EU5 psoriasis psoriatic arthritis psoriasis psoriatic arthritis diagnosed and diagnosed and diagnosed diagnosed treated treated 6.5m 5.2m 329k 390k moderate/severe moderate/severe biologic treated biologic treated patients patients 76k 52k
Slide 6: Mavrilimumab
Mavrilimumab Rheumatoid arthritis (RA) US EU5 Japan prevalence prevalence prevalence 2.4m 2.2m 670k diagnosed diagnosed diagnosed 2.1m 1.9m 580k treated treated treated 1.5m 1.3m 375k moderate-severe moderate-severe moderate-severe 1.2m 1.1m 350k biologic biologic biologic treated treated treated 53
Slide 7: Sifalimumab and anifrolumab
Sifalimumab and anifrolumab Lupus US EU5 Japan diagnosed diagnosed diagnosed 325k 170k 68k SLE lupus nephritis SLE lupus nephritis SLE lupus nephritis 254k 71k 138k 32k 53k 15k treated treated treated 228k 103k 48k biologic treated biologic treated biologic treated 15k 6k 2k SLE: Systemic Lupus Eryt
Slide 8: Type 2 Diabetes
Type 2 Diabetes US EU5 Japan China prevalence prevalence prevalence prevalence 31m 23m 10.5m 100m diagnosed diagnosed diagnosed diagnosed 23.5m (~76%) 18m (~80%) 8m (~77%) 44m (~44%) treated treated treated treated 19m (~81%) 15m (~84%) 6m (~77%) 28m (~64%) Source: Decision Resources Sept 2014 8 - E
Slide 9: Brilinta
Brilinta ACS, prior MI, stroke PEGASUS PLATO study* study* SOCRATES study** prior MI ischemic stroke ACS prevalence prevalence 13-36 months 4.0m 4.5m 2.2m STEMI NSTEMI unstable ASA treated / mild moderate / severe angina P2Y12 treated 1.2m 1.5m no therapy 1.2m 990k 1.4m 950k 3.6m P2Y12 treated P2Y12
Slide 10: Brilinta (continued)
Brilinta (continued) PAD, Type 2 Diabetes EUCLID Study* THEMIS Study** PAD prevalence type 2 diabetes prevalence 68m 200m diagnosed diagnosed / treated 17.5m 105m no history of ACS, stroke history of ACS, stroke no MI / stroke / (primary prevention) (secondary prevention) PAD history 13m 4.4m 65m P2
Slide 11: Epanova
Epanova Hypertriglyceridemia US EU5 Japan prevalence prevalence prevalence 315m 315m 128m HTG (>150 mg/dL) HTG (>150 mg/dL) HTG (>150 mg/dL) 64m 67m 31m HTG (>150 mg/dL) HTG (>150 mg/dL) HTG (>150 mg/dL) diagnosed & treated diagnosed & treated diagnosed & treated 15m 14m 6.5m patients on TG specific
Slide 12: Roxadustat
Roxadustat* Chronic kidney disease - NDD and DD stage 3 NDD stage 4 NDD stage 5 NDD dialysis 16.5m US / 27m China 900k US / 2.5m China 200k US / 800k China 630k US / 200k China Dx with anemia Dx with anemia Dx with anemia Dx with anemia 340k US / 650k China 45k US / 290k China 20k US / 150k China 57
Slide 13: Lynparza
Lynparza Ovarian cancer advanced treatable ovarian cancer 87.6k Geographic breakdown 1L drug treated 2L/3L drug treated 43.0k 41.0k gBRCA neg/ gBRCAm platinum refractory platinum sensitive unknown 34.7k 8.4k 16.4k 24.7k US EU5 ROW high risk g/sBRCAm 7.6k 8.5k platinum treated platinum treated 7.2k 7
Slide 14: AZD9291
Geographic breakdown AZD9291 EGFRm+ non-small cell lung cancer (NSCLC) US EU5 Japan U.S. EU5 Japan 1L drug treatable 1L drug treatable 1L drug treatable 150k 178k 94k 1L advanced 1L advanced 1L advanced drug treated drug treated drug treated 105k 125k 67k EGFRm- / unknown EGFRm+ EGFRm- / unknown EGF
Slide 15: MEDI4736 / MEDI4736 + tremelimumab
Geographic breakdown MEDI4736 / MEDI4736 + tremelimumab Non-small cell lung cancer (NSCLC) U.S. EU5 Japan US EU5 Japan 1L drug treatable 1L drug treatable 1L drug treatable NSCLC NSCLC NSCLC 150k 178k 94k 1L advanced drug 1L advanced drug 1L advanced drug treated treated treated 105k 125k 67k PDL1+
Slide 16: Metastatic NSCLC
Metastatic NSCLC Drug-treated patients EGFR / ALk WT EGFR m+ ALk 1st (240k) (48k) (9k) Line PDL1+ (40%) PDL1- (60%) 297k PDL1+ : 19k PDL1+: 4k 96k 144k PDL1- : 29k PDL1-: 5k 2nd EGFR m+ ALk (30k) (6k) Line 62k 93k PDL1+: 2k 191k PDL1+ : 12k PDL1- : 18k PDL1-: 4k Based on 2014 drug treated patient
Slide 17: Tremelimumab
Tremelimumab Mesothelioma Geographic breakdown prevalence 12k pleural / peritoneal other U.S. EU5 JP 98% 1L drug treated 8.0k 2L drug treated 4.0k Source: SEER/IARC; market research Based on 2014 patient numbers and treatment rates 17 - Epidemiology
Slide 18: Selumetinib
Selumetinib NSCLC, differentiated thyroid cancer (DTC), uveal melanoma (UM) NSCLC UM patients DTC patients 1L drug treatable 5k 100k 422k diagnosed and diagnosed and treated treated 1L 1L advanced drug 2L advanced drug treated treated 80k 2k 297k 231k high-risk receiving diagnosed and RAI treated 2L
Slide 19: Movantik / Moventig
Movantik / Moventig Opioid-induced constipation (OIC) US EU5 total opioid patients total opioid patients 95m 28.5m chronic non-cancer patients chronic non-cancer patients 23.5m (~25%) 14.2m (~50%) OIC OIC 16.2m (~69%) 6.3m (~44%) treated w/Rx or OTC laxative treated w/Rx or OTC laxative 11.1m (~69%)
Slide 20: CAZ AVI
CAZ AVI Serious gram-negative bacterial infection EU5 ROW gram-negative gram-negative hospital treated hospital treated 2.8m 29.5m access to Western access to Western meds meds 100% 32% resistant gram- resistant gram- negative with negative with access access 2.8m 9.5m HTI due to HTI due to HTI due
Slide 21: Epidemiology
Epidemiology This Epidemiology appendix contains estimates of patient data for a number of diseases and potential indications relevant for select AstraZeneca in-market products and pipeline projects. All data are based on reliable sources generally recognised and used by AstraZeneca for planning pur